- Home
- LMAT
as of 03-10-2026 3:40pm EST
$109.97
$0.10
-0.09%
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | BURLINGTON |
| Market Cap: | 2.0B | IPO Year: | 2006 |
| Target Price: | $105.80 | AVG Volume (30 days): | 217.1K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 2.52 | EPS Growth: | 30.57 |
| 52 Week Low/High: | $71.42 - $115.33 | Next Earning Date: | 05-28-2026 |
| Revenue: | $249,602,000 | Revenue Growth: | 13.53% |
| Revenue Growth (this year): | 13.66% | Revenue Growth (next year): | 8.97% |
| P/E Ratio: | 43.32 | Index: | N/A |
| Free Cash Flow: | 78.4M | FCF Growth: | +100.39% |
Stock Insider Trading Activity of LeMaitre Vascular Inc. (LMAT)
LeMaitre George W
Sell
Chairman and CEO
LMAT Mar 2, 2026
Avg Cost/Share
$107.81
Shares
55,930
Total Value
$6,030,020.24
Owned After
1,476,500
SEC Form 4
Roberts David B
Sell
President and Director
LMAT Feb 27, 2026
Avg Cost/Share
$106.80
Shares
8,464
Total Value
$903,957.74
Owned After
17,979
SEC Form 4
Kamke Trent G
Sell
Senior V. P., Operations
LMAT Feb 27, 2026
Avg Cost/Share
$110.29
Shares
1,044
Total Value
$115,142.76
Owned After
6,677
SEC Form 4
LeMaitre George W
Sell
Chairman and CEO
LMAT Feb 26, 2026
Avg Cost/Share
$106.76
Shares
150,000
Total Value
$16,013,355.00
Owned After
1,476,500
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| LeMaitre George W | LMAT | Chairman and CEO | Mar 2, 2026 | Sell | $107.81 | 55,930 | $6,030,020.24 | 1,476,500 | |
| Roberts David B | LMAT | President and Director | Feb 27, 2026 | Sell | $106.80 | 8,464 | $903,957.74 | 17,979 | |
| Kamke Trent G | LMAT | Senior V. P., Operations | Feb 27, 2026 | Sell | $110.29 | 1,044 | $115,142.76 | 6,677 | |
| LeMaitre George W | LMAT | Chairman and CEO | Feb 26, 2026 | Sell | $106.76 | 150,000 | $16,013,355.00 | 1,476,500 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 25, 2026 · 98% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 25, 2026 · 98% conf.
AI Prediction SELL
1D
-8.32%
$83.77
5D
-11.96%
$80.45
20D
-9.32%
$82.87
Price: $91.38 Prob +5D: 1% AUC: 1.000
0001193125-26-071954
8-K
LEMAITRE VASCULAR INC false 0001158895 0001158895 2026-02-25 2026-02-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2026
LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter)
Commission File Number: 001-33092
Delaware
04-2825458
(State or other jurisdiction of incorporation)
(IRS Employer Identification No.)
63 Second Avenue Burlington, MA 01803 (Address of principal executive offices, including zip code) 781-221-2266 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
Trading symbol
Name of exchange on which registered
Common stock, $0.01 par value per share
LMAT
The Nasdaq Global Market Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On February 25, 2026, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Report. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. Disclaimer on Forward-Looking Statements This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. Item 9.01. Financial Statements and Exhibits. The following exhibits are furnished or filed as part of this Report, as applicable: (d) Exhibits.
Exhibit No.
Description
99.1
Press release issued by LeMaitre Vascular, Inc. on February 25, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signature(s) Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LeMaitre Vascular, Inc.
Date: February 25, 2026
By:
Dorian LeBlanc /s/ DORIAN LEBLANC
Dorian LeBlanc Chief Financial Officer
Exhibit Index
Exhibit No.
Description
99.1
Press release issued by LeMaitre Vascular, Inc. on February 25, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 6, 2025
0001193125-25-269454
8-K
LEMAITRE VASCULAR INC false 0001158895 0001158895 2025-11-06 2025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025
LeMaitre Vascular, Inc. (Exact name of registrant as specified in its charter)
Commission File Number: 001-33092
Delaware
04-2825458
(State or other jurisdiction of incorporation)
(IRS Employer Identification No.)
63 Second Avenue Burlington, MA 01803 (Address of principal executive offices, including zip code) 781-221-2266 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
Trading symbol
Name of exchange on which registered
Common stock, $0.01 par value per share
LMAT
The Nasdaq Global Market Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 6, 2025, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Report. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. Disclaimer on Forward-Looking Statements This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
Item 9.01. Financial Statements and Exhibits.
The following exhibits are furnished or filed as part of this Report, as applicable:
(d) Exhibits.
Exhibit No.
Description
99.1
Press release issued by LeMaitre Vascular, Inc. on November 6, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signature(s) Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LeMaitre Vascular, Inc.
Date: November 6, 2025
By:
Dorian LeBlanc /s/ DORIAN LEBLANC
Dorian LeBlanc
Chief Financial Officer
Exhibit Index
Exhibit No.
Description
99.1
Press release issued by LeMaitre Vascular, Inc. on November 6, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
2025 Q2 Q2 2025 Earnings
8-K Aug 5, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 5, 2025
0001437749-25-024862
lmat20250805_8k.htm
false 0001158895
0001158895
2025-08-05 2025-08-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 5, 2025
LeMaitre Vascular, Inc.
(Exact name of registrant as specified in its charter)
Commission File Number: 001-33092
Delaware
04-2825458
(State or other jurisdiction of
(IRS Employer
incorporation)
Identification No.)
63 Second Avenue
Burlington, MA 01803
(Address of principal executive offices, including zip code)
781-221-2266
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
Trading symbol
Name of exchange on which registered
Common stock, $0.01 par value per share
LMAT
The Nasdaq Global Market
Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 5, 2025, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Report.
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Disclaimer on Forward-Looking Statements
This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
Item 9.01. Financial Statements and Exhibits.
The following exhibits are furnished or filed as part of this Report, as applicable:
(d)
Exhibits.
Exhibit No.
Description
99.1
Press release issued by LeMaitre Vascular, Inc. on August 5, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signature(s)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LeMaitre Vascular, Inc.
Date: August 5, 2025
By:
Dorian LeBlanc
/s/ DORIAN LEBLANC
Dorian LeBlanc
Chief Financial Officer
Exhibit Index
Exhibit No.
Description
99.1
Press release issued by LeMaitre Vascular, Inc. on August 5, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Latest LeMaitre Vascular Inc. News
LMAT Breaking Stock News: Dive into LMAT Ticker-Specific Updates for Smart Investing
Compare LMAT vs Leading Stocks
See how LMAT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LMAT LeMaitre Vascular Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.